Levetiracetam Orion

Levetiracetam, the active ingredient in Levetiracetam Orion, is an anticonvulsant presented as a tablet for oral use. It is employed to treat various seizure types in patients with epilepsy. GNH USA supplies Levetiracetam Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic medication that reduces abnormal neuronal firing in the brain.

- Partial‑onset seizures: helps achieve seizure control and reduce episode frequency. - Generalized tonic‑clonic seizures: contributes to seizure freedom and lowers risk of convulsive episodes. - Myoclonic seizures: diminishes myoclonic jerks and improves daily functioning.

Levetiracetam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired or low in energy. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Suicidal ideation: thoughts of self‑harm that must be reported promptly. - Severe rash or hypersensitivity: extensive skin eruptions or allergic response. - Blood dyscrasias: rare abnormalities in blood cell counts.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic impairment: use with caution; monitor liver function tests. - Psychiatric disorders: observe for mood changes or aggression. - Pregnancy: safety not established; weigh benefits against potential risks. - Elderly patients: start at lower dose and titrate slowly. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Levetiracetam can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Carbamazepine: reduces levetiracetam plasma levels. - Phenytoin: may decrease levetiracetam exposure. - Phenobarbital: can lower levetiracetam concentrations. - Enzyme‑inducing antiepileptics: overall decrease efficacy.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels. - Fluconazole: potential modest increase in exposure. - Oral contraceptives: monitor for reduced contraceptive effectiveness. - NSAIDs: watch for additive central nervous system effects.